other material
confidence high
sentiment positive
materiality 0.85
Phase 3 PANOVA-3 trial meets primary endpoint; median OS improved to 16.2 vs 14.2 months (HR 0.82, p=0.039)
NovoCure Ltd
- Median overall survival 16.2 months with TTFields + GnP vs 14.2 months for GnP alone; HR 0.82, p=0.039.
- One-year survival rate 68.1% vs 60.2% (p=0.029).
- Median pain-free survival 15.2 months vs 9.1 months; 6.1-month extension (HR 0.74, p=0.027).
- TTFields therapy well-tolerated with mild to moderate skin adverse events; no new safety signals.
- Company plans to file for FDA PMA approval in second half of 2025.